+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cannabis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 150 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4771910
UP TO OFF until Sep 30th 2022
The cannabis market is projected to register a CAGR of 15.4% during the forecast period 2022-2027.

Like in every other market, the COVID-19 pandemic had an adverse impact on the cannabis market as well. The imposition of lockdown limited consumers from visiting brick-and-mortar shops. However, many cannabis companies began relying heavily on social media and e-commerce platforms to market to consumers during this period. Cannabis retail outlets, producers, manufacturers, distributors, and warehouses were deemed essential services by the Alberta Government on March 30, 2020. As a result, cannabis businesses and services continued to serve Albertans throughout the COVID-19 pandemic.

The proven medicinal properties of cannabis, legalization of cannabis, active research into genetic development and modification of the plant, and advancements in intellectual property rights of cannabis are expected to be the major drivers of the market. The market's growth has been fueled by the continued adoption of legal medical or recreational cannabis in more countries worldwide, as well as high-profile achievements from some of the industry's emerging top contenders. With the first cannabis-based drug receiving approval from the US Food and Drug Administration (FDA), many investors are starting legal marijuana operations.​

North America dominates the market and is projected to be the fastest-growing region. The cannabis industry has been growing significantly in the United States due to the product’s use for medicinal purposes. As a result, the National Cannabis Industry Association (NCIA) is promoting the growth of the legal cannabis industry and providing it with favorable social, economic, and legal conditions in the United States. As a psychoactive drug, cannabis continues to find extensive favor among recreational and medicinal users in the United States.

Key Market Trends

Increasing Legalization of Cannabis is Driving the Market

Medicinal cannabis accounts for a significant share of the cannabis market. Many countries, such as Australia, Canada, Chile, Colombia, Germany, Greece, Israel, Italy, the Netherlands, Peru, Poland, Portugal, and Uruguay, have legalized the usage of cannabis for medicinal purposes. In March 2017, Germany legalized medicinal cannabis to supply cannabis products to the increasing patient demand. In Germany, medical cannabis products are sold exclusively in pharmacies, and they are prescribed by doctors as a last resort medicine, which means the patient has exhausted all other avenues of treatment. Further, the Croatian parliament allowed the cultivation and production of cannabis for medicinal purposes in the country in 2019.

As of July 2019, 11 states and Washington DC legalized the possession and personal use of marijuana for recreational purposes in the United States. On the other hand, 30 states in the United States legalized the usage of cannabis for medical purposes. More states are estimated to follow suit during the forecast period, considering the widespread demand for cannabis and its medicinal properties.

In US provinces, where cannabis has been legalized, consumers are mostly aged 50 years and above. Owing to the higher risk of chronic diseases post 50 years of age and the effectiveness of cannabis on such conditions, this demographic profile is expected to boost the demand for cannabis in the country. According to the US Government Accountability Office (under State Medical Marijuana Laws), symptoms and conditions that can be treated by cannabis include Alzheimer’s disease, anorexia, HIV-AIDS, glaucoma, cancer, arthritis, epilepsy, nausea, pain, cachexia, Crohn's disease, migraines, multiple sclerosis, spasticity, and wasting syndrome. Continuous research and standardization of products for medicinal purposes are expected to increase the popularity and demand for cannabis in the future.

North America Dominates the Market

The North American cannabis market is set to become the major producer of cannabis post the legalization of cannabis in Canada. In May 2021, the US government approved new growers of research marijuana for the first time in more than 50 years, thus, increasing the capacity to study the drug’s medical value.

Similarly, the Food and Drug Administration approved some of its derivative compounds for medicinal use. Marinol, Syndros, Cesamet, and Epidolex are cannabinoid drugs that received approval from the FDA. Furthermore, in the United States, ten states have legalized cannabis for recreational use, while 33 states and the District of Columbia have legalized cannabis for medical purposes. Among these states, California, Washington, and Colorado are the leading cannabis sellers. The production levels of cannabis in North America have increased rapidly over the past few years due to the expansion of the major players' production capacities. More states are estimated to follow suit during the forecast period, considering the widespread demand for cannabis and its medicinal properties. ​

Further, Statistics Canada data shows that compared to April-June 2019, people spent 74% more money on licensed cannabis during the same period in 2020 in the country, just after the World Health Organization declared the COVID-19 pandemic in March. This period saw increased consumption of cannabis and related products in the country.

Competitive Landscape

The cannabis market is extremely fragmented, with local and regional players occupying significant shares. In the cannabis market, companies are very active and are involved continuously in acquiring shares and developing new products to attract more consumers to their products.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Drivers
4.2 Market Restraints
4.3 Porter's Five Forces Analysis
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Buyers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitute Products
4.3.5 Intensity of Competitive Rivalry
5.1 Product Type
5.1.1 Capsules
5.1.2 Concentrates
5.1.3 Edibles
5.1.4 Other Product Types
5.2 Application
5.2.1 Medical
5.2.2 Recreational
5.3 Compound Type
5.3.1 Tetrahydrocannabinol (THC)
5.3.2 Cannabidiol (CBD)
5.3.3 Balanced THC & CBD
5.4 Geography
5.4.1 North America United States Canada Rest of North America
5.4.2 Europe Germany Czech Republic Croatia Rest of Europe
5.4.3 Asia-Pacific Australia Rest of Asia-Pacific
5.4.4 South America Argentina Chile Peru Rest of South America
5.4.5 Middle-East and Africa South Africa Rest of Middle-East and Africa
6.1 Most Adopted Strategies
6.2 Market Share Analysis
6.3 Company Profiles
6.3.1 Tilray
6.3.2 Canopy Growth Corp.
6.3.3 GW Pharmaceuticals PLC
6.3.4 Aurora Cannabis Inc.
6.3.5 Aphria Inc.
6.3.6 MedReLeaf Corp.
6.3.7 CV Sciences Inc.
6.3.8 Delta 9 Cannabis
6.3.9 Cannimed Therapeutics Inc.
6.3.10 Vivo Cannabis

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Tilray
  • Canopy Growth Corp.
  • GW Pharmaceuticals PLC
  • Aurora Cannabis Inc.
  • Aphria Inc.
  • MedReLeaf Corp.
  • CV Sciences Inc.
  • Delta 9 Cannabis
  • Cannimed Therapeutics Inc.
  • Vivo Cannabis